VipStockReports

Eye-Catching Stocks - FANNIE MAE PFD S(OTCBB:FNMAS), Provectus Pharmaceuticals, Inc.(OTCMKTS:PVCT), Gazprom OAO (ADR)(OTCMKTS:OGZPY) , Biozone Pharmaceuticals Inc(OTCBB:BZNE)

 
Repost This

Middletown, DE -- (SBWIRE) -- 10/03/2013 -- VipStockReports.com screens the markets looking for Hot Emerging Micro-cap and Small cap stocks that look to Run High. Our team STRONGLY believes the penny stock market can powerfully reward average traders, and we are here to lead the way. Today our focus is on: FANNIE MAE PFD S(OTCBB:FNMAS), Provectus Pharmaceuticals, Inc.(OTCMKTS:PVCT), Gazprom OAO (ADR)(OTCMKTS:OGZPY) , Biozone Pharmaceuticals Inc(OTCBB:BZNE)

FANNIE MAE PFD S(OTCBB:FNMAS) remained a volume gainer of 1.31 million shares and the average volume of the stock remained 932,036.00 shares. The stock opened the session at $5.78 and was recently trading at $5.82. The market capitalization of the stock remained 1.63 billion. The half-yearly trend of the stock remained positive 49.23%.

Is FNMAS a Solid Investment at These Levels? Read This Report For Details

In the recent trading session, Provectus Pharmaceuticals, Inc.(OTCMKTS:PVCT) exchanged 503,017.00 shares and the average volume remained 633,078.00 shares. The stock, in the current trading session, was at $0.775, with the drop of -0.64%. Tracking the three months and 6 months trends, the stock was at +17.42% and +17.42%, respectively. Provectus Pharmaceuticals, Inc. is a development-stage pharmaceutical company that is primarily engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The Company develops and focuses to license or market and sells its two prescription drug candidates, PV-10 and PH-10. The Company has transferred all its intellectual property related to over the counter (OTC) products and non-core technologies to its subsidiaries and designated, such subsidiaries as non-core to its primary business of developing its oncology and dermatology prescription drug candidates.

Has PVCT Found The Bottom And Ready To Gain Momentum? Find Out Here

Gazprom OAO (ADR)(OTCMKTS:OGZPY) decreased -1.12% and its trading price was $8.82 recently. The volume of the stock was 440,104.00 shares and the average volume remained 791,775.00 shares. Yesterday, the stock traded amid the day price range of $8.77 - $8.89. The market capitalization of the stock remained 105.58 billion. The beta of the stock remained +1.69. Gazprom OAO is a Russia-based company engaged in the operation of gas pipeline systems and gas supply to European countries. In addition, it is involved in the oil production and refining activities, as well as energy generation. It’s activities comprise exploration and production of gas, transportation of gas, sale of gas domestically and abroad, gas storage, production of crude oil and gas condensate.

Why Should Investors Buy OGZPY After theRecentFall? Just Go Here and Find Out

Biozone Pharmaceuticals Inc(OTCBB:BZNE) exchanged 2.26 million shares in the recent trading session, and its average trading remained 652,668.00 shares. BZNE dropped -0.93% and was trading at $0.535. The market capitalization of the stock remained 37.94 million. YTD trend of the stock was negative -81.83%. Biozone Pharmaceuticals, Inc. (Biozone Pharma), formerly International Surf Resorts, Inc., through its wholly owned subsidiary, BioZone Laboratories, Inc., which primarily is engaged in the business of developing and manufacturing over the counter (OTC) drug products and cosmetic and beauty products on behalf of third parties. In addition, through Biozone Pharma’s wholly owned subsidiaries, Equalan LLC and Baker Cummins Corp., the Company markets two lines of skin care products.

Will BZNE Get Buyers Even After The Recent Rally? Find Out Here

About VipStockReports.com:
We screen the markets looking for Hot Emerging Micro-cap and Small cap stocks that look to Run High. Once we find the 'Next Hot Penny Stock' with Monster Upside Potential we immediately Email it to you in our detailed VIP Report so you can Beat Rest of the Crowd!!

Our team STRONGLY believes the penny stock market can powerfully reward average traders, and we are here to lead the way.

Disclaimer:
VipstockReports.com newsletters and website: The disclaimer is to be read entirely and fully understood before using our website, or joining our newsletter email list. Never invest into a stock discussed on this website or the Vipstockalerts.com newsletter unless you can afford to lose your entire investment. Please consult with a certified financial advisor before making any investment decisions.

VipStockReports.com and any affiliates and information providers make no implied or express warranties on the information provided. Please verify quotes with your financial advisor before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies profiled on the VipstockReports.com web site and/or newsletter involve a high degree of volatility and risk, and all investors should know that they may lose a portion of or all of their investment if they decide to purchase any stocks.

Read Full Disclaimer at: http://www.vipstockreports.com/disclaimer/